# A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study

> **NCT06290505** · PHASE2 · RECRUITING · sponsor: **Australasian Gastro-Intestinal Trials Group** · enrollment: 54 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06290505
- **Lead sponsor:** Australasian Gastro-Intestinal Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-08
- **Primary completion:** 2027-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06290505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06290505, "A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06290505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*